{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:50:40Z","timestamp":1740099040044,"version":"3.37.3"},"reference-count":70,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780128119457"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1016\/b978-0-12-811945-7.00007-5","type":"book-chapter","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T18:48:55Z","timestamp":1520448535000},"page":"89-110","source":"Crossref","is-referenced-by-count":0,"title":["Access to High Price Medicines in Portugal"],"prefix":"10.1016","author":[{"given":"Filipa Alves","family":"da Costa","sequence":"first","affiliation":[]},{"given":"Ana Paula","family":"Martins","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0010","unstructured":"ACSS (Administra\u00e7\u00e3o Central do Sistema de Sa\u00fade). Monitoriza\u00e7\u00e3o Mensal RNCCI \u2013 Janeiro de 2017."},{"issue":"2","key":"10.1016\/B978-0-12-811945-7.00007-5_bib0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jpg.2014.03.001","article-title":"O impacto da hepatite C em Portugal","volume":"21","author":"Anjo","year":"2014","journal-title":"GE. J. Port. Gastrenterol."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0020","unstructured":"Caldeira S., Furtado C., Vieira I., Baptista A., PHIS Hospital Pharma Report,http:\/\/whocc.goeg.at\/Literaturliste\/Dokumente\/CountryInformationReports\/PHIS%20Hospital%20Pharma%20Portugal%202010.pdf accessed 6 July 2017."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejphar.2015.03.048","article-title":"Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products","volume":"759","author":"Cavagnaro","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/B978-0-12-811945-7.00007-5_bib0030","first-page":"451","article-title":"Impact of pharmaceutical counselling in minor health problems in rural Portugal","volume":"12","author":"Coelho","year":"2014","journal-title":"Pharm. Pract."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0035","unstructured":"Constitui\u00e7\u00e3o da Rep\u00fablica Portuguesa. VII Revis\u00e3o Constitucional. Artigo 64\u00b0.(2005)."},{"issue":"2","key":"10.1016\/B978-0-12-811945-7.00007-5_bib0040","first-page":"164","article-title":"Ethical and legal challenges of personalized medicine: paradigmatic examples of research, prevention, diagnosis and treatment","volume":"32","author":"Cordeiro","year":"2014","journal-title":"Rev. Port. Saude P\u00fablica."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0045","article-title":"Effects of economic recession on elderly patients\u2019 perceptions of access to health care and medicines in Portugal","author":"Costa","year":"2016","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0050","unstructured":"Delibera\u00e7\u00e3o n.\u00b0 76\/CA\/2015, em 18 de Junho de 2015. Di\u00e1rio da Rep\u00fablica n.\u00b0 4\/2016 de 7 de Janeiro. Regulation on authorisation for exceptional use."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0055","unstructured":"Delibera\u00e7\u00e3o n.\u00b0 139\/CD\/2014. Regulation on early access."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0060","unstructured":"Delibera\u00e7\u00e3o 622\/2016. Regulation of the Commission for Health Technology Assessment (CATs). Regulation on early access."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0065","unstructured":"Decreto-Lei 282\/95. Fee applied to the marketing of medicines."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0070","unstructured":"Decreto-Lei 97\/2015, de 1 de Junho. Creation of the Commission for Health Technology Assessment (CATs)."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0075","unstructured":"Despacho n.\u00b0 1612-A\/2017. Determines the prohibition to give away health information."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0080","unstructured":"Dire\u00e7\u00e3o Geral de Sa\u00fade (DGS). Diagnostic and Treatment of Non-Small Cell Lung Cancer. Norma 032\/2013."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0085","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrd3501","article-title":"Bridging the efficacy-effectiveness gap: a regulator\u2019s perspective on addressing variability of drug response","volume":"10","author":"Eichler","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/B978-0-12-811945-7.00007-5_bib0090","first-page":"426","article-title":"Adaptive licensing: taking the next step in the evolution of drug approval","volume":"91","author":"Eichler","year":"2012","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0095","unstructured":"European Medicines Agency (EMA). Recommendations on eligibility to PRIME scheme. November, 2016."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0100","unstructured":"European Commission\u2014Directorate General Economic and Financial Affairs. The Economic Adjustment Programme for Portugal. Sixth Review\u2014Autumn 2012. European Economy, Occasional Papers 124; 2012. Available at: http:\/\/ec.europa.eu\/ economy_\ufb01nance\/publications\/occasional_paper\/2012\/pdf\/ocp124_ en.pdf] and below the OECD average [OECD. Health at a glance 2015: OECD indicators. OECD Publishing, Paris; 2015. doi:http:\/\/dx.doi.org\/10.1787\/health_glance2015-en."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0105","unstructured":"European Commission. The 2015 Aging Report \u2013 Economic and budgetary projections for the 28 EU Member States (2013\u20132060). ISSN 1725-3217 (online)."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0110","unstructured":"European Observatory of Health Systems. Health systems in transition. HIT Portugal. Lisboa, April 2017."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0360","unstructured":"Eurostat, 2016. Eurostat database. Luxembourg, European Commission. Available from:http:\/\/ec.europa.eu\/eurostat\/data\/database."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0115","unstructured":"EXIGO CONSULTORES \u2013 Financiamento publico dos medicamentos em Portugal (2007\u20132011): avalia\u00e7\u00e3o da acessibilidade e dos crit\u00e9rios de decis\u00e3o sobre os medicamentos com novas substancias activas ou novas indica\u00e7\u00f5es terap\u00eauticas. Lisboa: EXIGO Consultores, Novembro de 2011."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0120","unstructured":"FIP (International Pharmaceutical Federation). Sustainability of Pharmacy Services: advancing Global Health. International overview of remuneration models for community and hospital pharmacy. 2015."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0125","first-page":"723","article-title":"Valor terap\u00eautico acrescentado","volume":"24","author":"Fontes Ribeiro","year":"2008","journal-title":"Rev. Port Clin. Geral."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.drudis.2012.08.009","article-title":"Orphan drugs: the regulatory environment","volume":"18","author":"Franco","year":"2013","journal-title":"Drug Discov. Today"},{"year":"2016","series-title":"Access to High-Priced Medicines in Hospital Settings in Europe: A Study in Four European Countries","author":"Hawlik","key":"10.1016\/B978-0-12-811945-7.00007-5_bib0335"},{"issue":"1","key":"10.1016\/B978-0-12-811945-7.00007-5_bib0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.healthpol.2011.10.011","article-title":"Do rheumatoid arthritis patients have equal access to treatment with new medicines?: tumour necrosis factor-alpha inhibitors use in four European countries","volume":"104","author":"Hoebert","year":"2012","journal-title":"Health Policy"},{"issue":"1","key":"10.1016\/B978-0-12-811945-7.00007-5_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.2012.04476.x","article-title":"Future of the European Union regulatory network in the context of the uptake of new medicines","volume":"76","author":"Hoebert","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0145","unstructured":"INFARMED. Comunicado de Imprensa. Acesso \u00e0 Inova\u00e7\u00e3o. Mais de 1200 doentes tratados com AUE. Setembro 2016."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0150","unstructured":"INFARMED. Relat\u00f3rio de Avalia\u00e7\u00e3o do Pedido de Comparticipa\u00e7\u00e3o de Medicamento para Uso Humano. Parecer Harvoni. 18 Fevereiro 2015."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0155","unstructured":"INFARMED. Infarmed reavalia comparticipa\u00e7\u00e3o de 115 medicamentos mais caros. Comunicado de Imprensa, 17 de Maio de 2016."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0160","unstructured":"INFARMED. Acesso \u00e0 inova\u00e7\u00e3o. Mais de 1200 doentes tratados com AUE. Comunicado de Imprensa, 9 de Setembro de 2016."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0165","unstructured":"INFARMED. Balan\u00e7o do Programa da Hepatite C. Comunicado de Imprensa, 28-07-2015."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0170","unstructured":"INFARMED. Monitoriza\u00e7\u00e3o Mensal do consumo de medicamentos em Meio hospitalar. Janeiro-Outubro 2016."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0175","unstructured":"INFARMED. Hepatite C - Monitoriza\u00e7\u00e3o dos Tratamentos. 5 de Dezembro 2016. Available at http:\/\/www.infarmed.pt\/documents\/15786\/0\/Hepatite+C\/dd545649-1042-42e9-b2d3-83db2bc34b11?version=1.0 (accessed 21\/12\/2016)."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0180","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s10198-012-0432-5","article-title":"Patients\u2019 access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries","volume":"14","author":"Laires","year":"2013","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0185","doi-asserted-by":"crossref","first-page":"630","DOI":"10.2471\/BLT.13.129114","article-title":"Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries","volume":"92","author":"Leopold","year":"2014","journal-title":"Bull. World Health Organ."},{"issue":"1","key":"10.1016\/B978-0-12-811945-7.00007-5_bib0190","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/annonc\/mdv506","article-title":"Early market access of oncologic drugs in the EU","volume":"27","author":"Martinalbo","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0195","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1007\/s11096-015-0140-1","article-title":"The organizational framework of community pharmacies in Europe","volume":"37","author":"Martins","year":"2015","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0200","unstructured":"Medicines Australia. COMPARE Study. March 2015"},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0205","unstructured":"OBIG. Access to essential medicines in Portugal. Commissioned by Health Action International Europe. July, 2009."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0210","unstructured":"OECD Health Statistics 2016."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0215","unstructured":"Observat\u00f3rio Portugu\u00eas dos Sistemas de Sa\u00fade (OPSS). Sa\u00fade: S\u00edndroma de nega\u00e7\u00e3o. 2014."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0220","unstructured":"Observat\u00f3rio Portugu\u00eas dos Sistemas de Sa\u00fade (OPSS). Acesso aos cuidados de sa\u00fade: um direito em risco? 2015."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0225","unstructured":"Observat\u00f3rio Portugu\u00eas dos Sistemas de Sa\u00fade (OPSS). Sa\u00fade: procuram-se novos caminhos. 2016."},{"issue":"5","key":"10.1016\/B978-0-12-811945-7.00007-5_bib0230","first-page":"1","article-title":"Pharmaceutical regulation in 15 Europenan countries review","volume":"18","author":"Panteli","year":"2016","journal-title":"Health Syst. Transit."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0235","unstructured":"Pordata. Available at http:\/\/www.pordata.pt\/Portugal Accessed 06 April 2017."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0240","unstructured":"Portaria n.\u00b0 195-D\/2015. Di\u00e1rio da Rep\u00fablica, 1.\u00aa s\u00e9rie\u2014N.\u00b0 125\u201430 de junho de 2015. Establishes the pharmacotherapeutic groups and subgroups that may be subject to reimbursement."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0245","unstructured":"Portaria n.\u00b0 195-A\/2015. Di\u00e1rio da Rep\u00fablica n.\u00ba 125\/2015, 1\u00ba Suplemento, S\u00e9rie I de 2015-06-30. Approves the common procedure for reimbursement and previous evaluation of medicines."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0250","unstructured":"Portaria n.\u00b0 359\/2017. Di\u00e1rio da Rep\u00fablica n.\u00ba 223\/2017, S\u00e9rie I de 2017-11-20. Defines the reference countries to consider in 2018 for the prices of new medicines authorised."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0255","unstructured":"Portaria no 137-A\/2012. Di\u00e1rio da Rep\u00fablica, 1.a s\u00e9rie\u2014No. 92 Establishes the rules for prescribing by Common International Denomination."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0260","unstructured":"PWC. (2013). Ensaios Cl\u00ednicos em Portugal. Junho 2013 http:\/\/www.apifarma.pt\/publicacoes\/siteestudos\/Documents\/EstudoInvestig.Clinica%20em%20Portugal.%20jun.2013.vf.pdf. Accessed 19\/12\/2016."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0265","series-title":"European observatory on health systems and policies","article-title":"The impact of the financial crisis on the health system and health in Portugal","author":"Sakellarides","year":"2014"},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0270","unstructured":"Regulation (EC) No 141\/2000 of the European Parliament and Council of 16 December 1999 on orphan medicinal products."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0275","unstructured":"RNCCI (Rede Nacional de Cuidados Continuados Integrados). Guia Pr\u00e1tico, Instituto da"},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0280","unstructured":"Schwartz, L. The 9 most expensive medicines in the world \u2013 Courtesy of Big Pharma. Alternet, 29 September 2015."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0285","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-6-42","article-title":"Pricing and reimbursement of orphan drugs: the need for more transparency","volume":"6","author":"Simoens","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0365","doi-asserted-by":"crossref","unstructured":"Silva, M., F\u00e9lix, J., Ferreira, D., Vandewalle, B., Guerra, I., Cure, S., Aldir, I., Carvalho, A., Macedo, G., Marinho, R.T., Pedroto, I., Ramalho, F., 2014. Sofosbuvir for the treatment of chronic Hepatitis C: A comprehensive cost-effectiveness analysis across Hcv genotypes, pretreatment conditions and Hiv co-infection. Value Health 17, A 3 2 3 \u2013 A 6 8 6.","DOI":"10.1016\/j.jval.2014.08.820"},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0290","unstructured":"Sousa (a), I., Ramos, R., Costa, M. Analysis of the global spending with orphan drugs on the Portuguese National Health Service. 8th European Conference on Rare Diseases & Orphan Products, 26\u201328 May 2016, Edinburgh."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0295","unstructured":"Sousa (b), I. Impacto Or\u00e7amental de Medicamentos \u00f3rf\u00e3os em Portugal. Trabalho de Projeto do Mestrado em Economia, na especialidade de Economia Financeira, apresentado \u00e0 Faculdade de Economia da Universidade de Coimbra para obten\u00e7\u00e3o do grau de Mestre."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0300","unstructured":"Teixeira, I, Vieira, I. INFARMED. Pharmaceutical pricing and reimbursement information. Portugal pharma profile. 2008."},{"issue":"1","key":"10.1016\/B978-0-12-811945-7.00007-5_bib0305","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1470-2045(15)00449-0","article-title":"Cancer drugs in 16 European countries, Australia and New Zealand: a cross-country price comparison study","volume":"17","author":"Vogler","year":"2016","journal-title":"Lancet. Oncol."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0310","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/bmj.316.7129.410","article-title":"Rationing access to health care","volume":"316","author":"Weale","year":"1998","journal-title":"BMJ."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0315","unstructured":"WHO, Regional office for Europe (2015), \u2018Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research\u2019, 2015."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0320","unstructured":"WHO. The selection and use of essential medicines. Report of the WHO Expert Committee, 2002. Technical Report Series 914: 14\u201317. Geneva: World Health Organization, 2002."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0325","unstructured":"WHO. The 19th WHO model list of essential medicines. Geneva: World Health Organization, 2015. http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/EML2015_8-May-15.pdf (accessed 9\/10\/ 2015)."},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0350","unstructured":"WorldBank, 2014. World Health Organization Global Health Expenditure database. Available from: https:\/\/data.worldbank.org\/indicator\/SH.XPD.TOTL.ZS."},{"year":"2011","series-title":"Final report: a comparative analysis of the role and impact of Health Technology Assessment","author":"Wilsdon","key":"10.1016\/B978-0-12-811945-7.00007-5_bib0355"},{"key":"10.1016\/B978-0-12-811945-7.00007-5_bib0340","first-page":"2011","article-title":"\u2018Differences in costs of and access to pharmaceutical products in the EU. Brussels: European Parliament\u2019","author":"Kanavos","year":"2011","journal-title":"Policy Dep. Econ. Sci. Policy"}],"container-title":["Equitable Access to High-Cost Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128119457000075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128119457000075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T08:11:33Z","timestamp":1570867893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128119457000075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9780128119457"],"references-count":70,"URL":"https:\/\/doi.org\/10.1016\/b978-0-12-811945-7.00007-5","relation":{},"subject":[],"published":{"date-parts":[[2018]]}}}